Predict your next investment

Corporation
HEALTHCARE | Drug Development
corridorpharma.com

See what CB Insights has to offer

Executives

4

Board of Directors

8

Corridor Pharmaceuticals Board of Directors

8 Board of directors

Corridor Pharmaceuticals has 8 board of directors, including Brian Halak.

Name

Firm

Work History

Other Seats

Brian Halak

Corridor Pharmaceuticals

Brian Halak

Experienced biotech investor with proven history of successful fundraising, deal sourcing, investing, board membership, and exiting. Also involved in the creation of multiple biotech companies including Tobira Therapeutics and WindMIL Therapeutics. CEO of WindMIL from inception through first two rounds of financing.

Corridor Pharmaceuticals

Geeta Vemuri

Experienced Founder with a demonstrated history of working in the venture capital and private equity industry. Skilled in Biotechnology, Life Sciences, Business Strategy, Pharmaceutical Industry, and Strategy. Strong business development professional with a Ph.D focused in Biochemistry from Indian Institute of Science (IISc) and MBA in Finance from Wharton Business School. Former board member or observer among others of True North therapeutics (acquired by Biovertis), SyntImmune (acquired by Alexion), Covagen (acquired by Janssen).

Corridor Pharmaceuticals

Matt Zuga

Matt Zuga has been the chief financial officer and chief operating officer since June 2020. Since October 2013, Mr. Zuga has been a co-founder and partner of HighCape, and he brings more than 25 years of life sciences investment and banking experience. From August 2012 to September 2013, Mr. Zuga was a managing director of Syngenta Ventures Pte Ltd, an investment vehicle of Syngenta Corp. He was also the founder and managing member of Red Abbey, an investment company, from January 2004 to August 2012. Prior to Red Abbey, Mr. Zuga was a managing director and the head of life sciences investment banking at Legg Mason from 1999 to 2003. He is currently on the boards of Aziyo Biologics, Inc., AgriMetis, LLC, Alba Therapeutics Corporation, MF Fire, Inc. and Virtue Labs LLC. Mr. Zuga received an MBA from the Kenan-Flagler Business School at the University of North Carolina at Chapel Hill and a B.S. in Business Administration/Finance from Ohio State University. Mr. Zuga’s qualifications to serve on the board include his extensive experience in the life sciences industry, his network of contacts in the industry and his background in investing and investment banking.

Corridor Pharmaceuticals

Peter Greenleaf

Peter Greenleaf is the President of MedImmune LLC, the worldwide biologics business for AstraZeneca PLC. Since joining the company in 2006 as senior vice president, commercial operations, Peter has overseen the development of the company's global marketing and portfolio organizations, as well as managing the broader commercial, corporate development and strategy functions. He has also been accountable for MedImmune Ventures, a corporate development investment group. In addition to being a member of the MedImmune Executive Team, Peter has led the cross-functional Brand Management Team and been a member of the company's Product Development Committee.</br></br>Mr. Greenleaf joined MedImmune from Centocor, Inc., where he served as vice president of the gastroenterology franchise, responsible for sales, marketing, strategic planning and business development. He joined Centocor's cardiovascular division in 1998 and later moved into the immunology business, holding a number of positions with increasing responsibility in sales and marketing. Previously, he was employed in sales and marketing capacities with Boehringer Mannheim Corporation and US Healthcare, Inc.</br></br>Mr. Greenleaf holds a bachelor of science degree from Western Connecticut State University, and a master's degree in business administration from St. Joseph's University.

Corridor Pharmaceuticals

Name

Brian Halak

Brian Halak

Geeta Vemuri

Matt Zuga

Peter Greenleaf

Firm

Work History

Experienced biotech investor with proven history of successful fundraising, deal sourcing, investing, board membership, and exiting. Also involved in the creation of multiple biotech companies including Tobira Therapeutics and WindMIL Therapeutics. CEO of WindMIL from inception through first two rounds of financing.

Experienced Founder with a demonstrated history of working in the venture capital and private equity industry. Skilled in Biotechnology, Life Sciences, Business Strategy, Pharmaceutical Industry, and Strategy. Strong business development professional with a Ph.D focused in Biochemistry from Indian Institute of Science (IISc) and MBA in Finance from Wharton Business School. Former board member or observer among others of True North therapeutics (acquired by Biovertis), SyntImmune (acquired by Alexion), Covagen (acquired by Janssen).

Matt Zuga has been the chief financial officer and chief operating officer since June 2020. Since October 2013, Mr. Zuga has been a co-founder and partner of HighCape, and he brings more than 25 years of life sciences investment and banking experience. From August 2012 to September 2013, Mr. Zuga was a managing director of Syngenta Ventures Pte Ltd, an investment vehicle of Syngenta Corp. He was also the founder and managing member of Red Abbey, an investment company, from January 2004 to August 2012. Prior to Red Abbey, Mr. Zuga was a managing director and the head of life sciences investment banking at Legg Mason from 1999 to 2003. He is currently on the boards of Aziyo Biologics, Inc., AgriMetis, LLC, Alba Therapeutics Corporation, MF Fire, Inc. and Virtue Labs LLC. Mr. Zuga received an MBA from the Kenan-Flagler Business School at the University of North Carolina at Chapel Hill and a B.S. in Business Administration/Finance from Ohio State University. Mr. Zuga’s qualifications to serve on the board include his extensive experience in the life sciences industry, his network of contacts in the industry and his background in investing and investment banking.

Peter Greenleaf is the President of MedImmune LLC, the worldwide biologics business for AstraZeneca PLC. Since joining the company in 2006 as senior vice president, commercial operations, Peter has overseen the development of the company's global marketing and portfolio organizations, as well as managing the broader commercial, corporate development and strategy functions. He has also been accountable for MedImmune Ventures, a corporate development investment group. In addition to being a member of the MedImmune Executive Team, Peter has led the cross-functional Brand Management Team and been a member of the company's Product Development Committee.</br></br>Mr. Greenleaf joined MedImmune from Centocor, Inc., where he served as vice president of the gastroenterology franchise, responsible for sales, marketing, strategic planning and business development. He joined Centocor's cardiovascular division in 1998 and later moved into the immunology business, holding a number of positions with increasing responsibility in sales and marketing. Previously, he was employed in sales and marketing capacities with Boehringer Mannheim Corporation and US Healthcare, Inc.</br></br>Mr. Greenleaf holds a bachelor of science degree from Western Connecticut State University, and a master's degree in business administration from St. Joseph's University.

Other Seats

Corridor Pharmaceuticals

Corridor Pharmaceuticals

Corridor Pharmaceuticals

Corridor Pharmaceuticals

Corridor Pharmaceuticals

Corridor Pharmaceuticals Management Team

4 Team Members

Corridor Pharmaceuticals has 4 executives. Corridor Pharmaceuticals's founder is Dan Berkowitz. Corridor Pharmaceuticals's former Chief Executive Officer is Gary Lessing.

Name

Work History

Title

Status

Dan Berkowitz

Founder

Current

David Christianson

Founder

Current

Gary Lessing

Chief Executive Officer

Former

Peter S Suzdak

Chief Security Officer

Former

Name

Dan Berkowitz

David Christianson

Gary Lessing

Peter S Suzdak

Work History

Title

Founder

Founder

Chief Executive Officer

Chief Security Officer

Status

Current

Current

Former

Former

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.